Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies.
本週一，Prime Medicine Inc.（納斯達克:PRME）宣佈與Bristol Myers Squibb＆Co（紐交所:BMY）達成戰略研究合作和許可協議，共同開發用於下一代離體t細胞療法的試劑。
Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology.
根據協議條款，Prime Medicine將設計優化的Prime Editor試劑，針對若干目標，包括使用其Prime Assisted Site-Specific Integrase Gene Editing（PASSIGE）技術的試劑。
Also Read: Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst.
分析師稱：臨床前階段公司Prime Medicine的基因編輯平台具有潛力。
Bristol Myers Squibb will be responsible for developing, manufacturing, and commercializing next-generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.
Bristol Myers Squibb將負責開發、製造和商業化下一代細胞療法，Prime Medicine將在基因編輯策略和試劑開發方面提供支持。
Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb.
Prime Medicine將獲得Bristol Myers Squibb提前付款5500萬美元和5500萬美元的股權投資。
Prime Medicine is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
Prime Medicine還有權獲得超過35億美元的里程碑獎勵，包括高達14億美元的開發里程碑和超過21億美元的商業化里程碑，以及淨銷售額提成。
Concurrently, Prime Medicine announced that it would streamline its pipeline.
與此同時，Prime Medicine宣佈將簡化其產品線。
The company said it will focus on developing two programs for chronic granulomatous disease (CGD).
該公司表示將專注於爲慢性肉芽腫病（CGD）開發兩個項目。
- PM359, an ex vivo autologous hematopoietic stem cell (HSC) product: The company has initiated a Phase 1/2 clinical trial to assess the safety, biological activity, and preliminary efficacy of PM359 in adult and pediatric patients and expects initial clinical data study in 2025.
- Ex vivo HSC product for the treatment of X-linked CGD
- PM359是一種體外自體造血幹細胞（HSC）產品：該公司已經啓動了一項階段1/2臨床試驗，以評估PM359在成人和兒童患者中的安全性、生物活性和初步療效，並預計在2025年進行初步臨床數據研究。
- 用於治療X連鎖遺傳性過氧化物酶缺乏症的體外HSC產品
Other candidates that the company will prioritize include:
該公司將優先考慮的其他候選者包括：
- Lipid nanoparticle (LNP) Prime Editor for Wilson's Disease: Prime Medicine expects to present new preclinical data and initiate IND-enabling activities in the fourth quarter of 2024 and intends to file an IND and/or clinical trial application in the first half of 2026.
- LNP / adeno-associated virus Prime Editors for the treatment of Cystic Fibrosis.
- 用於威爾遜氏病的脂質納米粒（LNP）Prime Editor：Prime Medicine預計將於2024年第四季度展示新的臨床前數據，並啓動IND啓動活動，並計劃在2026年上半年提交IND和/或臨床試驗申請。
- 用於治療囊性纖維化的脂質納米粒（LNP）/腺相關病毒Prime Editor。
With the $110 million upfront consideration received from Bristol Myers Squibb under the strategic research collaboration and license agreement announced this morning, Prime Medicine expects its cash runway to fund operations into the first half of 2026.
通過宣佈今天早晨與百時美施貴寶達成的戰略研究合作和許可協議獲得的1.1億美元的預付款，Prime Medicine預計其現金運營能力將支持至2026年上半年。
Prime Medicine is identifying partnership opportunities to advance its other programs, including those for neurological diseases, cell therapy, ocular diseases, and hearing loss.
Prime Medicine正在尋找合作機會，推進其其他項目，包括神經疾病、細胞治療、眼科疾病和聽力喪失項目。
Price Action: PRME stock is up 17.1% at $4.05 during the premarket session at last check Monday.
價格走勢：PRME股票在週一的盤前交易時上漲了17.1%，報價4.05美元。
Photo via Shutterstock
圖片來自shutterstock。
- What's Going On With Alibaba Stock On Monday?
- 阿里巴巴股票星期一發生了什麼？
譯文內容由第三人軟體翻譯。